Wednesday, December 07, 2022

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POCTM Platform

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POCTM Platform
  • The deal will initially cover the UK and France with the potential to expand to other European countries and around the world.

Newcastle upon Tyne, England and Florence, Italy, 2 November 2022 /PRNewswire/ — QuantuMDX Group Limited (“QuantuMDX”), a UK-based developer of point-of-need transformative molecular diagnostics, and A. Menarini Diagnostics Mr. (Menarini), announce an exclusive distribution agreement for QuantumDX’s Q are pleased. -POC platform in the UK and France.

Under the terms of the agreement, Menarini will market, sell and service QuantuMDX’s Q-POC SARS-CoV-2 Assay and its new SARS-CoV-2, Flu A/B, RSV Respiratory Panel Test, which the company initially introduced. was launched. of this year. deal [de cinco años] Will initially cover distribution in the UK and France, with the possibility of expanding to other markets.

Jonathan O’HalloranQuantumMDX CEO said: “This agreement with Menarini is an important business step for QuantumMDX. Menarini not only has an extensive global network, but their country-specific knowledge and presence across Europe and beyond means they are an excellent partner for us The agreement will allow us to further accelerate commercial sales of Q-POC, bringing our point-of-need multiplex molecular diagnostics platform to clinical and non-clinical settings in several new markets. I look forward to working closely with Menarini in what I believe will be a very successful partnership.”

Fabio Piazzalunga, Global Director of Menarini Diagnostics Mr. comments: “The recent pandemic has highlighted the importance of being able to diagnose infectious diseases accurately and quickly. QuantumDX’s Q-PoC platform, which can provide results in about 30 minutes, enables healthcare professionals to make informed treatment decisions. and transmission. Menarini is a leader in the decentralization of diagnostic routines and has developed core competencies and technologies in doing so. We are able to provide such an innovative platform to laboratories in the UK and France But very happy.”

About Quantum MDX

QuantumDX is a progressive medical technology company passionate about empowering the world to control disease and reduce suffering. QuantumDX solves real-world clinical problems by creating multiplexed molecular solutions for the point of need.

QuantumDX has global operational and strategic partnerships, which places it at the forefront of molecular diagnostics.

The Q-POC is a fast, easy-to-use and portable sample-to-response multiplex PCR device. It is designed for use in a variety of real-world health care settings.

Q-POC and its first test, a multiplex SARS-CoV-2 detection assay, CE-IVD have been labeled under the In Vitro Diagnostics Directive (98/79/EC) for use within the Union European and the UK. allows. On 26 May, Q-POC received the CE mark under IVDR (EU Regulation 2017/746).

QuantumDX plans to begin a series of syndromic multiplex testing assays in the coming months and years.

To learn more about QuantumDX and Q-PoC, its rapid point-of-care PCR system, visit:,

About A. Menarini Diagnostics, Human Touch of Technology:

The company has been dedicated for more than 45 years to helping healthcare professionals make safe and sustainable diagnoses, thereby improving the quality of life for people around the world.

a. Menarini Diagnostics is part of the Menarini Pharmaceutical Group, established in 1886. Today it is present in 140 countries around the world, has more than 17,000 employees and in 2021 its turnover is 3,922 million euros.

More information in:,

World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.

Latest News

Related Stories

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Thanks for submitting your comment!